# Ilaris (Canakinumab) in the Schnitzler Syndrome

> **NCT01245127** · PHASE2 · COMPLETED · sponsor: **Universitaire Ziekenhuizen KU Leuven** · enrollment: 1 (actual)

## Conditions studied

- Schnitzler Syndrome

## Interventions

- **DRUG:** Ilaris

## Key facts

- **NCT ID:** NCT01245127
- **Lead sponsor:** Universitaire Ziekenhuizen KU Leuven
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2011-08
- **Final completion:** 2012-05
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2019-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01245127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01245127, "Ilaris (Canakinumab) in the Schnitzler Syndrome". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01245127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*